Antioxidants and atherogenesis

Journal of Nutritional Biochemistry

Volumn 9, Issue 8, 1998, Pages 424-445

  Schwenke, Dawn C ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Carotene; Antioxidants; Atherosclerosis; Fruit; Vegetable; Vitamin C; Vitamin E

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; FLUINDOSTATIN; PRAVASTATIN; PROBUCOL; RAMIPRIL; RETINOL; SELENIUM; SIMVASTATIN; ZINC;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; FRUIT; HUMAN; OXIDATION; OXIDATIVE STRESS; REVIEW; VEGETABLE;

EID: 0031725852     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-2863(98)00046-1     Document Type: Review

References (281)

1. Levy R.I. Declining mortality in coronary heart disease. Arteriosclerosis. 1:1981;312-325.
2. Hjermann I., Holme I., Velve Byre K., Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease Report from the Oslo Study Group of a randomised trial in healthy men . Lancet. 2:1981;1303-1310.
3. The Lipid Research Clinics Coronary Primary Prevention Trial Results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering . JAMA. 251:1984;365-374.
4. Berenson G.S., Wattigney W.A., Tracy R.E., Newman W.P., Srinivasan S.R., Webber L.S., Dalferes E.R., Strong J.P. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am. J. Cardiol. 70:1992;851-858.
5. Pekkanen J., Linn S., Heiss G., Suchindran C.M., Leon A., Rifkind B.M., Tyroler H.A. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N. Engl. J. Med. 322:1990;1700-1707.
6. Ross R. Atherosclerosis A defense mechanism gone awry . Am. J. Pathol. 143:1993;987-1002.
7. St. Clair R.W. Pathogenesis of atherosclerosis. Cardiol. Rev. 5:1997;14-71.
8. Quinn M.T., Parthasarathy S., Fong L.G., Steinberg D. Oxidatively modified low density lipoproteins A potential role in recruitment and retention of monocyte/macrophages during atherogenesis . Proc. Natl. Acad. Sci. U.S.A. 84:1987;2995-2998.
9. Stary H.C., Chandler A.B., Glagov S., Guyton J.R., Insull W. Jr, Rosenfeld M.E., Schaffer S.A., Schwartz C.J., Wagner W.D., Wissler R.W. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association . Circulation. 89:1994;2462-2478.
10. Stary H.C., Chandler A.B., Dinsmore R.E., Fuster V., Glagov S., Insull W., Rosenfeld M.E., Schwartz C.J., Wagner W.D., Wissler R.W. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association . Circulation. 92:1995;1355-1374.
11. Schwenke D.C., Carew T.E. Initiation of atherosclerotic lesions in cholesterol-fed rabbits I. Focal increases in arterial LDL concentration precede development of fatty streak lesions . Arteriosclerosis. 9:1989;895-907.
12. Schwenke D.C., Carew T.E. Initiation of atherosclerotic lesions in cholesterol-fed rabbits II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries . Arteriosclerosis. 9:1989;908-918.
13. Felton C.V., Crook D., Davies M.J., Oliver M.F. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler. Thromb. Vasc. Biol. 17:1997;1337-1345.
14. Stender S., Zilversmit D.B. Transfer of plasma lipoprotein components and of plasma proteins into aortas of cholesterol-fed rabbits Molecular size as a determinant of plasma lipoprotein influx . Arteriosclerosis. 1:1981;38-49.
15. Stender S., Hjelms E. In vivo transfer of cholesteryl ester from high and low density plasma lipoproteins into human aortic tissue. Arteriosclerosis. 8:1988;252-262.
16. Henriksen T., Mahoney E.M., Steinberg D. Enhanced macrophage degradation of biologically modified low density lipoprotein. Arteriosclerosis. 3:1983;149-159.
17. Heinecke J.W., Rosen H., Suzuki L.A., Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoproteins by arterial smooth muscle cells. J. Biol. Chem. 262:1987;10098-10103.
18. Hiramatsu K., Rosen H., Heinecke J.W., Wolfbauer G., Chait A. Superoxide initiates oxidation of low density lipoprotein by human monocytes. Arteriosclerosis. 7:1987;55-60.
19. Parthasarathy S., Printz D.J., Boyd D., Joy L., Steinberg D. Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor. Arteriosclerosis. 6:1986;505-510.
20. Lamb D.J., Wilkins G.M., Leake D.S. The oxidative modification of low density lipoprotein by human lymphocytes. Atherosclerosis. 92:1992;187-192.
21. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., Hansson G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U.S.A. 92:1995;3893-3897.
22. Rosenfeld M.E., Khoo J.C., Miller E., Parthasarathy S., Palinski W., Witztum J.L. Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of low-density lipoproteins, and contain oxidation-specific lipid-protein adducts. J. Clin. Invest. 87:1991;90-99.
23. Francis G.A., Oram J.F., Heinecke J.W., Bierman E.L. Oxidative tyrosylation of HDL enhances the depletion of cellular cholesteryl esters by a mechanism independent of passive sterol desorption. Biochemistry. 35:1996;15188-15197.
24. Francis G.A., Mendez A.J., Bierman E.L., Heinecke J.W. Oxidative tyrosylation of high density lipoprotein by peroxidase enhances cholesterol removal from cultured fibroblasts and macrophage foam cells. Proc. Natl. Acad. Sci. U.S.A. 90:1993;6631-6635.
25. Nagano Y., Arai H., Kita T. High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc. Natl. Acad. Sci. U.S.A. 88:1991;6457-6461.
26. Rifici V.A., Khachadurian A.K. Effects of dietary vitamin C and E supplementation on the copper mediated oxidation of HDL and on HDL mediated cholesterol efflux. Atherosclerosis. 127:1996;19-26.
27. Rifici V.A., Khachadurian A.K. Oxidation of high density lipoproteins Characterization and effects on cholesterol efflux from J774 macrophages . Biochim. Biophys. Acta. 1299:1996;87-94.
28. Parthasarathy S., Young S.G., Witztum J.L., Pittman R.C., Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J. Clin. Invest. 77:1986;641-644.
29. Babiy A.V., Gebicki J.M., Sullivan D.R., Willey K. Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation. Biochem. Pharmacol. 43:1992;995-1000.
30. Parthasarthy S., Barnett J. Phospholipase A2 activity of low density lipoprotein Evidence for an intrinsic phospholipase A2 activity of apoprotein B-100 . Proc. Natl. Acad. Sci. U.S.A. 87:1990;9741-9745.
31. Quinn M.T., Parthasarathy S., Steinberg D. Lysophosphatidylcholine A chemotactic factor for human monocytes and its potential role in atherogenesis . Proc. Natl. Acad. Sci. U.S.A. 85:1988;2805-2809.
32. Cushing S.D., Berliner J.A., Valente A.J., Territo M.C., Navab M., Parhami F., Gerrity R., Schwartz C.J., Fogelman A.M. Minimally modified low density lipoprotein induces monocyte chemotactic protein-1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. U.S.A. 87:1990;5134-5138.
33. Cominacini L., Garbin U., Pasini A.F., Davoli A., Campagnola M., Contessi G.B., Pastorino A.M., Locascio V. Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Radic. Biol. Med. 22:1997;117-127.
34. Sluiter W., Pietersma A., Lamers J.M.J., Koster J.F. Leukocyte adhesion molecules on the vascular endothelium - Their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression. J. Cardiovasc. Pharmacol. 22:1993;S37-S44.
35. Fruebis J., Gonzalez V., Silvestre M., Palinski W. Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and m-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 17:1997;1289-1302.
36. Ferns G.A.A., Forster L., Stewartlee A., Nouroozzadeh J., Anggard E.E. Probucol inhibits mononuclear cell adhesion to vascular endothelium in the cholesterol-fed rabbit. Atherosclerosis. 100:1993;171-181.
37. Rajavashisth T.B., Andalibi A., Territo M.C., Berliner J.A., Navab M., Fogelman A.M., Lusis A.J. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature. 344:1990;254-257.
38. Klinkner A.M., Waites C.R., Kerns W.D., Bugelski P.J. Evidence of foam cell and cholesterol crystal formation in macrophages incubated with oxidized LDL by fluorescence and electron microscopy. J. Histochem. Cytochem. 43:1995;1071-1078.
39. Wiklund O., Mattsson L., Björnheden T., Camejo G., Bondjers G. Uptake and degradation of low density lipoproteins in atherosclerotic rabbit aorta Role of local LDL modification . J. Lipid Res. 32:1991;55-62.
40. Sparrow C.P., Parthasarathy S., Steinberg D. A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. J. Biol. Chem. 264:1989;2599-2604.
41. Han J.H., Hajjar D.P., Febbraio M., Nicholson A.C. Native and modified low density lipoproteins increase the functional expression of the macrophage class b scavenger receptor, CD36. J. Biol. Chem. 272:1997;21654-21659.
42. Carew T.E., Schwenke D.C., Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit . Proc. Natl. Acad. Sci. U.S.A. 84:1987;7725-7729.
43. Autio I., Jaakkola O., Solakivi T., Nikkari T. Oxidized low-density lipoprotein is chemotactic for arterial smooth muscle cells in culture. FEBS Lett. 277:1990;247-249.
44. Bjorkerud B., Bjorkerud S. Contrary effects of lightly and strongly oxidized LDL with potent promotion of growth versus-apoptosis on arterial smooth muscle cells, macrophages, and fibroblasts. Arterioscler. Thromb. Vasc. Biol. 16:1996;416-424.
45. Sakai M., Miyazaki A., Hakamata H., Kodama T., Suzuki H., Kobori S., Shichiri M., Horiuchi S. The scavenger receptor serves as a route for internalization of lysophosphatidylcholine in oxidized low density lipoprotein-induced macrophage proliferation. J. Biol. Chem. 271:1996;27346-27352.
46. Chai Y.C., Howe P.H., DiCorleto P.E., Chisolm G.M. Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells - Evidence for release of fibroblast growth factor-2. J. Biol. Chem. 271:1996;17791-17797.
47. Yuan X.M., Li W., Olsson A.G., Brunk U.T. The toxicity to macrophages of oxidized low-density lipoprotein is mediated through lysosomal damage. Atherosclerosis. 133:1997;153-161.
48. Suc I., Escargueil-Blanc I., Troly M., Salvayre R., Nègre-Salvayre A. HDL and apoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 17:1997;2158-2166.
49. Jovinge S., Crisby M., Thyberg J., Nilsson J. DNA fragmentation and ultrastructural changes of degenerating cells in atherosclerotic lesions and smooth muscle cells exposed to oxidized LDL in vitro. Arterioscler. Thromb. Vasc. Biol. 17:1997;2225-2231.
50. Escargueil-Blanc I., Meilhac O., Pieraggi M.T., Arnal J.F., Salvayre R., Nègre-Salvayre A. Oxidized LDLs induce massive apoptosis of cultured human endothelial cells through a calcium-dependent pathway-prevention by aurintricarboxylic acid. Arterioscler. Thromb. Vasc. Biol. 17:1997;331-339.
51. Nishio E., Arimura S., Watanabe Y. Oxidized LDL induces apoptosis in cultured smooth muscle cells A possible role for 7-ketocholesterol . Biochem. Biophys. Res. Commun. 223:1996;413-418.
52. Thorne S.A., Abbot S.E., Winyard P.G., Blake D.R., Mills P.G. Extent of oxidative modification of low density lipoprotein determines the degree of cytotoxicity to human coronary artery cells. Heart. 75:1996;11-16.
53. Auge N., Pieraggi M.T., Thiers J.C., Nègre-Salvayre A., Salvayre R. Proliferative and cytotoxic effects of mildly oxidized low-density lipoproteins on vascular smooth-muscle cells. Biochem. J. 309:1995;1015-1020.
54. Stiko-Rahm A., Hultgårdh-Nilsson A., Regnstrom J., Hamsten A., Nilsson J. Native and oxidized LDL enhances production of PDGF-AA and the surface expression of PDGF receptors in cultured human smooth muscle cells. Arterioscler. Thromb. 12:1992;1099-1109.
55. Porreca E., Difebbo C., Barbacane R.C., Panara M.R., Cuccurullo F., Conti P. Effect of interleukin-1 receptor antagonist on vascular smooth muscle cell proliferation. Atherosclerosis. 99:1993;71-78.
56. Kockx M.M., Demeyer G.R.Y., Muhring J., Bult H., Bultinck J., Herman A.G. Distribution of cell replication and apoptosis in atherosclerotic plaques of cholesterol-fed rabbits. Atherosclerosis. 120:1996;115-124.
57. Rekhter M.D., Gordon D. Active proliferation of different cell types, including lymphocytes, in human atherosclerotic plaques. Am. J. Pathol. 147:1995;668-677.
58. Bjorkerud S., Bjorkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am. J. Pathol. 149:1996;367-380.
59. Kugiyama K., Sakamoto T., Misumi I., Sugiyama S., Ohgushi M., Ogawa H., Horiguchi M., Yasue H. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ. Res. 73:1993;335-343.
60. Weis J.R., Pitas R.E., Wilson B.D., Rodgers G.M. Oxidized low-density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation. FASEB J. 5:1991;2459-2465.
61. Aviram M. LDL-platelet interaction under oxidative stress induces macrophage foam cell formation. Thromb. Haemost. 74:1995;560-564.
62. Camejo G., Fager G., Rosengren B., Hurt-Camejo E., Bondjers G. Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J. Biol. Chem. 268:1993;14131-14137.
63. Falcone D.J., Salisbury B.G.J. Fibronectin stimulates macrophage uptake of low density lipoprotein-heparin-collagen complexes. Arteriosclerosis. 8:1988;263-273.
64. Vijayagopal P., Srinivasan S.R., Xu J.H., Dalferes E.R. Jr, Radhakrishnamurthy B., Berenson G.S. Lipoprotein-proteoglycan complexes induce continued cholesteryl ester accumulation in foam cells from rabbit atherosclerotic lesions. J. Clin. Invest. 91:1993;1011-1018.
65. Srinivasan S.R., Xu J.H., Vijayagopal P., Radhakrishnamurthy B., Berenson G.S. Low-density lipoprotein binding affinity of arterial chondroitin sulfate proteoglycan variants modulates cholesteryl ester accumulation in macrophages. Biochim. Biophys. Acta. 1272:1995;61-67.
66. Hurt-Camejo E., Camejo G., Rosengren B., Lopez F., Ahlstrom C., et al. Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells. Arterioscler. Thromb. 12:1992;569-583.
67. Lipton B.A., Parthasarathy S., Ord V.A., Clinton S.K., Libby P., Rosenfeld M.E. Components of the protein fraction of oxidized low density lipoprotein stimulate interleukin-1 alpha production by rabbit arterial macrophage-derived foam cells. J. Lipid Res. 36:1995;2232-2242.
68. Lee E., Grodzinsky A.J., Libby P., Clinton S.K., Lark M.W., Lee R.T. Human vascular smooth muscle cell-monocyte interactions and metalloproteinase secretion in culture. Arterioscler. Thromb. Vasc. Biol. 15:1995;2284-2289.
69. Galis Z.S., Muszynski M., Sukhova G.K., Simon-Morrissey E., Unemori E.N., Lark M.W., Amento E., Libby P. Cytokine-stimulated vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ. Res. 75:1994;181-189.
70. Yao P.M., Maitre B., Delacourt C., Buhler J.M., Harf A., Lafuma C. Divergent regulation of 92-kDa gelatinase and TIMP-1 by HBECs in response to IL-1 beta and TNF-alpha. Am. J. Physiol. 273:1997;L866-L874.
71. Faxon D.P., Coats W., Currier J. Remodeling of the coronary artery after vascular injury. Prog. Cardiovasc. Dis. 40:1997;129-140.
72. Lafont A.M., Chai Y.C., Cornhill J.F., Whitlow P.L., Howe P.H., Chisolm G.M. Effect of alpha-tocopherol on restenosis after angioplasty in a model of experimental atherosclerosis. J. Clin. Invest. 95:1995;1018-1025.
73. Konneh M.K., Rutherford C., Li S.R., Anggard E.E., Ferns G.A.A. Vitamin E inhibits the intimal response to balloon catheter injury in the carotid artery of the cholesterol-fed rat. Atherosclerosis. 113:1995;29-39.
74. Boscoboinik D., Szewczyk A., Hensey C., Azzi A. Inhibition of cell proliferation by alpha-tocopherol Role of protein kinase-C . J. Biol. Chem. 266:1991;6188-6194.
75. Chatelain E., Boscoboinik D.O., Bartoli G.M., Kagan V.E., Gey F.K., Packer L., Azzi A. Inhibition of smooth muscle cell proliferation and protein kinase-C activity by tocopherols and tocotrienols. Biochim. Biophys. Acta. 1176:1993;83-89.
76. Evensen S.A., Galdal K.S., Nilsen E. LDL-induced cytotoxicity and its inhibition by anti-oxidant treatment in cultured human endothelial cells and fibroblasts. Atherosclerosis. 49:1983;23-30.
77. Guyton J.R., Lenz M.L., Mathews B., Hughes H., Karsan D., Selinger E., Smith C.V. Toxicity of oxidized low density lipoproteins for vascular smooth muscle cells and partial protection by antioxidants. Atherosclerosis. 118:1995;237-249.
78. Marchant C.E., Law N.S., Vanderveen C., Hardwick S.J., Carpenter K.L.H., Mitchinson M.J. Oxidized low-density lipoprotein is cytotoxic to human monocyte-macrophages Protection with lipophilic antioxidants . FEBS Lett. 358:1995;175-178.
79. Haendeler J., Zeiher A.M., Dimmeler S. Vitamin C and E prevent lipopolysaccharide-induced apoptosis in human endothelial cells by modulation of Bcl-2 and Bax. Eur. J. Pharmacol. 317:1996;407-411.
80. O'Brien K., Nagano Y., Gown A., Kita T., Chait A. Probucol treatment affects the cellular composition but not anti-oxidized low density lipoprotein immunoreactivity of plaques from Watanabe heritable hyperlipidemic rabbits. Arterioscler. Thromb. 11:1991;751-759.
81. Braesen J.H., Beisiegel U., Niendorf A. Probucol inhibits not only the progression of atherosclerotic disease, but causes a different composition of atherosclerotic lesions in WHHL-rabbits. Virchows Archiv. 426:1995;179-188.
82. Chang M.Y., Sasahara M., Chait A., Raines E.W., Ross R. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol 2. Cellular composition and proliferation . Arterioscler. Thromb. Vasc. Biol. 15:1995;1631-1640.
83. Ferns G.A.A., Forster L., Stewart-Lee A., Konneh M., NouroozZadeh J., Änggård E.E. Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit. Proc. Natl. Acad. Sci. U.S.A. 89:1992;11312-11316.
84. Devaraj S., Li D., Jialal I. The effects of alpha tocopherol supplementation on monocyte function - Decreased lipid oxidation, interleukin-1 beta secretion, and monocyte adhesion to endothelium. J. Clin. Invest. 98:1996;756-763.
85. Williams S.P., Mason R.M. Modulation of proteoglycan synthesis by bovine vascular smooth muscle cells during cellular proliferation and treatment with heparin. Arch. Biochem. Biophys. 287:1991;386-396.
86. Majors A.K., Ehrhart L.A. Cell density and proliferation modulate collagen synthesis and procollagen messenger RNA levels in arterial smooth muscle cells. Exp. Cell Res. 200:1992;168-174.
87. Ting H.H., Timimi F.K., Haley E.A., Roddy M.A., Ganz P., Creager M.A. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation. 95:1997;2617-2622.
88. Ting H.H., Timimi F.K., Boles K.S., Creager S.J., Ganz P., Creager M.A. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 97:1996;22-28.
89. Andersson T.L.G., Matz J., Ferns G.A.A., Anggard E.E. Vitamin E reverses cholesterol-induced endothelial dysfunction in the rabbit coronary circulation. Atherosclerosis. 111:1994;39-45.
90. Galley H.F., Thornton J., Howdle P.D., Walker B.E., Webster N.R. Combination oral antioxidant supplementation reduces blood pressure. Clin. Sci. 92:1997;361-365.
91. Daugherty A., Zweifel B.S., Schonfeld G. Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br. J. Pharmacol. 98:1989;612-618.
92. Kita T., Nagano Y., Yokode M., Ishii K., Kume N., Coshima A., Yoshida H., Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. U.S.A. 84:1987;5928-5931.
93. Bocan T.M.A., Mueller S.B., Brown E.Q., Uhlendorf P.D., Mazur M.J., Newton R.S. Antiatherosclerotic effects of antioxidants are lesion-specific when evaluated in hypercholesterolemic New Zealand white rabbits. Exp. Mol. Pathol. 57:1992;70-83.
94. Hodis H.N., Chauhan A., Hashimoto S., Crawford D.W., Sevanian A. Probucol reduces plasma and aortic wall oxysterol levels in cholesterol-fed rabbits independently of its plasma cholesterol lowering effect. Atherosclerosis. 96:1992;125-134.
95. Fruebis J., Steinberg D., Dresel H.A., Carew T.E. A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits. J. Clin. Invest. 94:1994;392-398.
96. Bjorkhem I., Henriksson-Freyschuss A., Breuer O., Diczfalusy U., Berglund L., Henriksson P. The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler. Thromb. 11:1991;15-22.
97. Sparrow C.P., Doebber T.W., Olszewski J., Wu M.S., Ventre J., Stevens K.A., Chao Y.S. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N′-diphenyl-phenylenediamine. J. Clin. Invest. 89:1992;1885-1891.
98. Hoppe G., Ravandi A., Herrera D., Kuksis A., Hoff H.F. Oxidation products of cholesteryl linoleate are resistant to hydrolysis in macrophages, form complexes with proteins, and are present in human atherosclerotic lesions. J. Lipid Res. 38:1997;1347-1360.
99. Breuer O., Dzeletovic S., Lund E., Diczfalusy U. The oxysterols cholest-5-ene-3 beta,4 alpha-diol, cholest-5-ene-3 beta,4 beta-diol and cholestane-3 beta,5 alpha,6 alpha-triol are formed during in vitro oxidation of low density lipoprotein, and are present in human atherosclerotic plaques. Biochim. Biophys. Acta. 1302:1996;145-152.
100. Ylä-Herttuala S., Palinski W., Rosenfeld M.E., Parthasarathy S., Carew T.E., Butler S., Witztum J.L., Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84:1989;1086-1095.
101. Leeuwenburgh C., Hardy M.M., Hazen S.L., Wagner P., Ohishi S., et al. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J. Biol. Chem. 272:1997;1433-1436.
102. Haberland M.E., Fong D., Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 241:1988;215-218.
103. Boyd H.C., Gown A.M., Wolfbauer G., Chait A. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am. J. Pathol. 135:1989;815-825.
104. Rosenfeld M.E., Palinski W., Ylä-Herttuala S., Butler S., Witztum J.L. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 10:1990;336-349.
105. O'Brien K.D., Alpers C.E., Hokanson J.E., Wang S., Chait A. Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein. Circulation. 94:1996;1216-1225.
106. Morel D.W., Delalleramoya M., Friday K.E. Treatment of cholesterol-fed rabbits with dietary vitamins E and C inhibits lipoprotein oxidation but not development of atherosclerosis. J. Nutr. 124:1994;2123-2130.
107. Sasahara M., Raines E.W., Chait A., Carew T.E., Steinberg D., Wahl P.W., Ross R. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol 1. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J. Clin. Invest. 94:1994;155-164.
108. Akeson A.L., Woods C.W., Mosher L.B., Thomas C.E., Jackson R.L. Inhibition of IL-1β expression in THP-1 cells by probucol and tocopherol. Atherosclerosis. 86:1991;261-270.
109. Tsujita M., Yokoyama S. Selective inhibition of free apolipoprotein-mediated cellular lipid efflux by probucol. Biochemistry. 35:1996;13011-13020.
110. Li S.R., Forster L., Änggård E., Ferns G. The effects of LPS and probucol on interleukin-1 (IL-1) and platelet-derived growth factor (PDGF) gene expression in the human monocytic cell line U-937. Biochim. Biophys. Acta. 1225:1994;271-274.
111. McPherson R., Hogue M., Milne R.W., Tall A.R., Marcel Y.L. Increase in plasma cholesteryl ester transfer protein during probucol treatment - Relation to changes in high density lipoprotein composition. Arterioscler. Thromb. 11:1991;476-481.
112. Chiesa G., Michelagnoli S., Cassinotti M., Gianfranceschi G., Werba J.P., Pazzucconi F., Sirtori C.R., Franceschini G. Mechanisms of high-density lipoprotein reduction after probucol treatment - Changes in plasma cholesterol esterification/transfer and lipase activities. Metabolism. 42:1993;229-235.
113. Zhang S.H., Reddick R.L., Avdievich E., Surles L.K., Jones R.G., Reynolds J.B., Quarfordt S.H., Maeda N. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J. Clin. Invest. 99:1997;2858-2866.
114. Franceschini G., Chiesa G., Sirtori C.R. Probucol increases cholesteryl ester transfer protein activity in hypercholesterolaemic patients. Eur. J. Clin. Invest. 21:1991;384-388.
115. Dinchuk J., Hart J., Gonzalez G., Karmann G., Schmidt D., Wirak D.O. Remodelling of lipoproteins in transgenic mice expressing human cholesteryl ester transfer protein. Biochim. Biophys. Acta. 1255:1995;301-310.
116. Tall A.R. Plasma cholesteryl ester transfer protein (Review). J. Lipid Res. 34:1993;1255-1274.
117. Melchior G.W., Greenlee K.A., Castle C.K., Prough M.J., Milne R.W., Marotti K.R., Kezdy F.J. Evidence that cynomolgus monkey cholesteryl ester transfer protein has two neutral lipid binding sites. J. Biol. Chem. 270:1995;21068-21074.
118. McPherson R., Lau P., Kussie P., Barrett H., Tall A.R. Plasma kinetics of cholesteryl ester transfer protein in the rabbit - Effects of dietary cholesterol. Arterioscler. Thromb. Vasc. Biol. 17:1997;203-210.
119. Ishigami M., Yamashita S., Sakai N., Hirano K.I., Arai T., Maruyama T., Takami S., Koyama M., Kamedatakemura K., Matsuzawa Y. High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur. J. Clin. Invest. 27:1997;285-292.
120. Regnstrom J., Walldius G., Nilsson S., Elinder L.S., Johansson J., et al. The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. Atherosclerosis. 125:1996;217-229.
121. Thomas M.J., Thornburg T., Manning J., Hooper K., Rudel L.L. Fatty acid composition of low-density lipoprotein influences its susceptibility to autoxidation. Biochemistry. 33:1994;1828-1834.
122. Reaven P., Parthasarathy S., Grasse B.J., Miller E., Almazan F., et al. Feasibility of using an oleate-rich diet to reduce the susceptibility of low-density lipoprotein to oxidative modification in humans. Am. J. Clin. Nutr. 54:1991;701-706.
123. Reaven P., Parthasarathy S., Grasse B.J., Miller E., Steinberg D., Witztum J.L. Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modification in mildly hypercholesterolemic subjects. J. Clin. Invest. 91:1993;668-676.
124. Bonanome A., Pagnan A., Biffanti S., Opportuno A., Sorgato F., Dorella M., Maiorino M., Ursini F. Effect of dietary monounsaturated and polyunsaturated fatty acids on the susceptibility of plasma low density lipoproteins to oxidative modification. Arterioscler. Thromb. 12:1992;529-533.
125. Leren P. The Oslo Diet-Heart Study. Eleven-year report. Circulation. 42:1970;935-942.
126. Turpeinen O. Effect of cholesterol-lowering diet on mortality from coronary heart disease and other causes. Circulation. 59:1979;1-7.
127. Oliver M.F. It is more important to increase the intake of unsaturated fats than to decrease the intake of saturated fats Evidence from clinical trials relating to ischemic heart disease . Am. J. Clin. Nutr. 66:1997;S980-S986.
128. Blankenhorn D.H., Johnson R.L., Mack W.J., el Zein H.A., Vailas L.I. The influence of diet on the appearance of new lesions in human coronary arteries. JAMA. 263:1990;1646-1652.
129. Tell G.S., Evans G.W., Folsom A.R., Shimakawa T., Carpenter M.A., Heiss G. Dietary fat intake and carotid artery wall thickness The Atherosclerosis Risk in Communities (ARIC) Study . Am. J. Epidemiol. 139:1994;979-989.
130. Keys A., Menotti A., Karvonen M-J, Aravanis C., Blackburn H., Buzina R., Djordjevic B.S., Dontas A.S., Fidanza F., Keys M.H., Kromhout D., Nedeljkovic S., Punsar S., Seccareccia F., Toshima H. The diet and 15-year death rate in the Seven Countries Study. Am. J. Epidemiol. 124:1986;908-915.
131. Keys A. Coronary heart disease in seven countries 17. The Diet . Circulation. 41:(suppl 1):1970;162-183.
132. Katsouyanni K., Skalkidis Y., Petridou E., Polychronopoulou-Trichopoulou A., Willett W., Trichopoulos D. Diet and peripheral arterial occlusive disease the role of poly-, mono-, and saturated fatty acids . Am. J. Epidemiol. 133:1991;24-31.
133. Rudel L.L., Parks J.S., Sawyer J.K. Compared with dietary monounsaturated and saturated fat, polyunsaturated fat protects African green monkeys from coronary artery atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15:1995;2101-2110.
134. Watts G.F., Jackson P., Mandalia S., Brunt J.N.H., Lewis E.S., Coltart D.J., Lewis B. Nutrient intake and progression of coronary artery disease. Am. J. Cardiol. 73:1994;328-332.
135. Hodgkin D.D., Boucek R.J., Purdy R.E., Pearce W.J., Fraser I.M., Gilbert R.D. Dietary lipids modify receptor- and non-receptor-dependent components of alpha1-adrenoceptor-mediated contraction. Am. J. Physiol. 261:1991;R1465-R1469.
136. Berry E.M., Eisenberg S., Haratz D., Friedlander Y., Norman Y., Kaufmann N.A., Stein Y. Effects of diets rich in monounsaturated fatty acids on plasma lipoproteins - The Jerusalem Nutrition Study High MUFAs vs high PUFAs . Am. J. Clin. Nutr. 53:1991;899-907.
137. Suzukawa M., Abbey M., Clifton P., Nestel P.J. Enhanced capacity of n-3 fatty acid-enriched macrophages to oxidize low density lipoprotein mechanisms and effects of antioxidant vitamins. Atherosclerosis. 124:1996;157-169.
138. Kilsdonk E.P.C., Dorsman A.N.R.D., Vangent T., Vantol A. Effect of phospholipid fatty acid composition of endothelial cells on cholesterol efflux rates. J. Lipid Res. 33:1992;1373-1382.
139. Dusserre E., Pulcini T., Bourdillon M.C., Ciavatti M., Berthezene F. Omega-3 fatty acids in smooth muscle cell phospholipids increase membrane cholesterol efflux. Lipids. 30:1995;35-41.
140. Williams K.J., Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15:1995;551-561.
141. Ramasamy S., Lipke D.W., Boissonneault G.A., Guo H.T., Hennig B. Oxidized lipid-mediated alterations in proteoglycan metabolism in cultured pulmonary endothelial cells. Atherosclerosis. 120:1996;199-208.
142. Oorni K., Pentikainen M.O., Annila A., Kovanen P.T. Oxidation of low density lipoprotein particles decreases their ability to bind to human aortic proteoglycans - Dependence on oxidative modification of the lysine residues. J. Biol. Chem. 272:1997;21303-21311.
143. Ramasamy S., Boissonneault G.A., Lipke D.W., Hennig B. Proteoglycans and endothelial barrier function - Effect of linoleic acid exposure to porcine pulmonary artery endothelial cells. Atherosclerosis. 103:1993;279-290.
144. Carmena R., Ascaso J.F., Camejo G., Varela G., Hurt-Camejo E., Ordovas J.M., Martinezvalls J., Bergstom M., Wallin B. Effect of olive and sunflower oils on low density lipoprotein level, composition, size, oxidation and interaction with arterial proteoglycans. Atherosclerosis. 125:1996;243-255.
145. Manning J.M., Gebre A.K., Edwards I.J., Wagner W.D., Rudel L.L., Parks J.S. Dietary polyunsaturated fat decreases interaction between low density lipoproteins and arterial proteoglycans. Lipids. 29:1994;635-641.
146. Fielding C.J., Fielding P.E. Molecular physiology of reverse cholesterol transport - Review. J. Lipid Res. 36:1995;211-228.
147. Cader A.A., Steinberg F.M., Mazzone T., Chait A. Mechanisms of enhanced macrophage apoe secretion by oxidized LDL. J. Lipid Res. 38:1997;981-991.
148. Mazzone T., Reardon C. Expression of heterologous human apolipoprotein E by J774 macrophages enhances cholesterol efflux to HDL(3). J. Lipid Res. 35:1994;1345-1353.
149. Hara S., Shike T., Takasu N., Mizui T. Lysophosphatidylcholine promotes cholesterol efflux from mouse macrophage foam cells. Arterioscler. Thromb. Vasc. Biol. 17:1997;1258-1266.
150. Sola R., Motta C., Maille M., Bargallo M.T., Boisnier C., Richard J.L., Jacotot B. Dietary monounsaturated fatty acids enhance cholesterol efflux from human fibroblasts - Relation to fluidity, phospholipid fatty acid composition, overall composition, and size of HDL3. Arterioscler. Thromb. 13:1993;958-966.
151. Sola R., Laville A.E., Richard J.L., Motta C., Bargallo M.T., Girona J., Masana L., Jacotot B. Oleic acid-rich diet protects against the oxidative modification of high density lipoprotein. Free Radic. Biol. Med. 22:1997;1037-1045.
152. Esteva O., Baudet M.F., Lasserre M., Jacotot B. Influence of the fatty acid composition of high-density lipoprotein phospholipids on the cholesterol efflux from cultured fibroblasts. Biochim. Biophys. Acta. 875:1986;174-182.
153. Daugherty A., Dunn J.L., Rateri D.L., Heinecke J.W. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94:1994;437-444.
154. Todd S., Woodward M., Boltonsmith C., Tunstallpedoe H. An investigation of the relationship between antioxidant vitamin intake and coronary heart disease in men and women using discriminant analysis. J. Clin. Epidemiol. 48:1995;297-305.
155. Street D.A., Comstock G.W., Salkeld R.M., Schuep W., Klag M.J. Serum antioxidants and myocardial infarction - Are low levels of carotenoids and alpha-tocopherol risk factors for myocardial infarction? Circulation. 90:1994;1154-1161.
156. Kardinaal A.F.M., Kok F.J., Ringstad J., Gomezaracena J., Mazaev V.P., Kohlmeier L., Martin B.C., Aro A., Kark J.D., Delgadorodriguez M., Riemersma R.A., Vantveer P., Huttunen J.K., Martinmoreno J.M. Antioxidants in adipose tissue and risk of myocardial infarction - The EURAMIC Study. Lancet. 342:1993;1379-1384.
157. Elaaser A.A., Zakhary N.I., Elguindy S.M., Hafiez A.R.A., Halawa F., Mokhtar N. Effect of soybean, Vicia faba, and vitamin C on the carcinogenicity of DMBA. Nutr. Cancer. 22:1994;195-200.
158. Iribarren C., Folsom A.R., Jacobs D.R., Gross M.D., Belcher J.D., Eckfeldt J.H. Association of serum vitamin levels, LDL susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis - A case-control study. Arterioscler. Thromb. Vasc. Biol. 17:1997;1171-1177.
159. Regnstrom J., Nilsson J., Moldeus P., Strom K., Bavenholm P., Tornvall P., Hamsten A. Inverse relation between the concentration of low-density lipoprotein vitamin E and severity of coronary artery disease. Am. J. Clin. Nutr. 63:1996;377-385.
160. Mezzetti A., Lapenna D., Pierdomenico S.D., Calafiore A.M., Costantini F., Riariosforza G., Imbastaro T., Neri M., Cuccurullo F. Vitamins E, C and lipid peroxidation in plasma and arterial tissue of smokers and non-smokers. Atherosclerosis. 112:1995;91-99.
161. Rimm E.B., Stampfer M.J., Ascherio A., Giovannucci E., Colditz G.A., Willett W.C. Vitamin E consumption and the risk of coronary heart disease in men. N. Engl. J. Med. 328:1993;1450-1456.
162. Stampfer M.J., Hennekens C.H., Manson J.E., Colditz G.A., Rosner B., Willett W.C. Vitamin-E consumption and the risk of coronary disease in women. New Engl. J. Med. 328:1993;1444-1449.
163. Knekt P., Reunanen A., Jarvinen R., Seppanen R., Heliovaara M., Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am. J. Epidemiol. 139:1994;1180-1189.
164. Meyer F., Bairati I., Dagenais G.R. Lower ishemic heart disease incidence and mortality among vitamin supplement users. Can. J. Cardiol. 12:1996;930-934.
165. Kushi L.H., Folsom A.R., Prineas R.J., Mink P.J., Wu Y., Bostick R.M. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N. Engl. J. Med. 334:1996;1156-1162.
166. Losonczy K.G., Harris T.B., Havlik R.J. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons The established populations for epidemiologic studies of the elderly . Am. J. Clin. Nutr. 64:1996;190-196.
167. Hodis H.N., Mack W.J., Labree L., Cashinhemphill L., Sevanian A., Johnson R., Azen S.P. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA. 273:1995;1849-1854.
168. Azen S.P., Qian D.J., Mack W.J., Sevanian A., Selzer R.H., Liu C.R., Liu C.H., Hodis H.N. Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. Circulation. 94:1996;2369-2372.
169. Kritchevsky S.B., Shimakawa T., Tell G.S., Dennis B., Carpenter M., Eckfeldt J.H., Peacherryan H., Heiss G. Dietary antioxidants and carotid artery wall thickness The ARIC study . Circulation. 92:1995;2142-2150.
170. Gey K.F., Puska P., Jordan P., Moser U.K. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am. J. Clin. Nutr. 53:1991;S326-S334.
171. Gaziano J.M., Manson J.E., Branch L.G., Colditz G.A., Willet W.C., Buring J.E. A prospective study of consumption of carotenoids in fruits and vegetables and decreased cardiovascular mortality in the elderly. Ann. Epidemiol. 5:1995;255-260.
172. Pandey D.K., Shekelle R., Selwyn B.J., Tangney C., Stamler J. Dietary vitamin C and beta-carotene and risk of death in middle-aged men - The Western Electric Study. Am. J. Epidemiol. 142:1995;1269-1278.
173. Morris D.L., Kritchevsky S.B., Davis C.E. Serum carotenoids and coronary heart disease The lipid research clinics coronary primary prevention trial and follow-up study . JAMA. 272:1994;1439-1441.
174. Gale C.R., Martyn C.N., Winter P.D., Cooper C. Vitamin C and risk of death from stroke and coronary heart disease in cohort of elderly people. Br. Med. J. 310:1995;1563-1566.
175. Nyyssonen K., Parviainen M.T., Salonen R., Tuomilehto J., Salonen J.T. Vitamin C deficiency and risk of myocardial infarction Prospective population study of men from eastern Finland . Br. Med. J. 314:1997;634-638.
176. Salvini S., Hennekens C.H., Morris J.S., Willett W.C., Stampfer M.J. Plasma levels of the antioxidant selenium and risk of myocardial infarction among U.S. physicians. Am. J. Cardiol. 76:1995;1218-1221.
177. Kok F.J., Vanpoppel G., Melse J., Verheul E., Schouten E.G., Kruyssen D.H.C.M., Hofman A. Do antioxidants and polyunsaturated fatty acids have a combined association with coronary atherosclerosis? Atherosclerosis. 86:1991;85-90.
178. Bonithonkopp C., Coudray C., Berr C., Touboul P.J., Feve J.M., Favier A., Ducimetiere P. Combined effects of lipid peroxidation and antioxidant status on carotid atherosclerosis in a population aged 59-71 y The EVA Study . Am. J. Clin. Nutr. 65:1997;121-127.
179. Peng Y.M., Peng Y.S., Lin Y.G., Moon T., Roe D.J., Ritenbaugh C. Concentrations and plasma-tissue-diet relationships of carotenoids, retinoids, and tocopherols in humans. Nutr. Cancer. 23:1995;233-246.
180. Houston D.K., Johnson M.A., Daniel T.D., Poon L.W. Health and dietary characteristics of supplement users in an elderly population. Int. J. Vitam. Nutr. Res. 67:1997;183-191.
181. Dyer R.G., Stewart M.W., Mitcheson J., George K., Alberti M.M., Laker M.F. 7-Ketocholesterol, a specific indicator of lipoprotein oxidation, and malondialdehyde in non-insulin-dependent diabetes and peripheral vascular disease. Clin. Chim. Acta. 260:1997;1-13.
182. Prasad K., Kalra J. Oxygen-free radicals and hypercholesterolemic atherosclerosis Effect of vitamin E . Am. Heart J. 125:1993;958-973.
183. Qiao Y., Yokoyama M., Kameyama K., Asano G. Effect of vitamin E on vascular integrity in cholesterol-fed guinea pigs. Arterioscler. Thromb. 13:1993;1885-1892.
184. Nourooz-Zadeh J., Tajaddini-Sarmadi J., McCarthy S., Betteridge D.J., Wolff S.P. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes. 44:1995;1054-1058.
185. McEneny J., Loughrey C.M., McNamee P.T., Trimble E.R., Young I.S. Susceptibility of VLDL to oxidation in patients on regular haemodialysis. Atherosclerosis. 129:1997;215-220.
186. Karmansky I., Shnaider H., Palant A., Gruener N. Plasma lipid oxidation and susceptibility of low-density lipoproteins to oxidation in male patients with stable coronary artery disease. Clin. Biochem. 29:1996;573-579.
187. Morrow J.D., Roberts L.J. The isoprostanes Unique bioactive products of lipid peroxidation . Prog. Lipid Res. 36:1997;1-21.
188. Morrow J.D., Frei B., Longmire A.W., Gaziano J.M., Lynch S.M., Shyr Y., Strauss W.E., Oates J.A., Roberts L.J. Increase in circulating products of lipid peroxidation (F-2-isoprostanes) in smokers - Smoking as a cause of oxidative damage. N. Engl. J. Med. 332:1995;1198-1203.
189. Salonen J.T., Nyyssonen K., Salonen R., Porkkalasarataho E., Tuomainen T.P., Diczfalusy U., Bjorkhem I. Lipoprotein oxidation and progression of carotid atherosclerosis. Circulation. 95:1997;840-845.
190. Kontush A., Reich A., Baum K., Spranger T., Finckh B., Kohlschutter A., Beisiegel U. Plasma ubiquinol-10 is decreased in patients with hyperlipidaemia. Atherosclerosis. 129:1997;119-126.
191. Lagendijk J., Ubbink J.B., Vermaak J.H. Measurement of the ratio between the reduced and oxidized forms of coenzyme Q(10) in human plasma as a possible marker of oxidative stress. J. Lipid Res. 37:1996;67-75.
192. Derijke Y.B., Bredie S.J.H., Demacker P.N.M., Vogelaar J.M., Haklemmers H.L.M., Stalenhoef A.F.H. The redox status of coenzyme q10 in total LDL as an indicator of in vivo oxidative modification - Studies on subjects with familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 17:1997;127-133.
193. Salonen J.T., Ylä-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., Nyyssonen K., Palinski W., Witztum J.L. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 339:1992;883-887.
194. Maggi E., Chiesa R., Melissano G., Castellano R., Astore D., Grossi A., Finardi G., Bellomo G. LDL oxidation in patients with severe carotid atherosclerosis - A study of in vitro and in vivo oxidation markers. Arterioscler. Thromb. 14:1994;1892-1899.
195. Bergmark C., Wu R., Defaire U., Lefvert A.K., Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 15:1995;441-445.
196. Vandevijver L.P.L., Steyger R., Vanpoppel G., Boer J.M.A., Kruijssen D.A.C.M., Seidell J.C., Princen H.M.G. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis. 122:1996;245-253.
197. Puurunen M., Manttari M., Manninen V., Tenkanen L., Alfthan G., Ehnholm C., Vaarala O., Aho K., Palosuo T. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch. Intern. Med. 154:1994;2605-2609.
198. Kleinveld H.A., Haklemmers H.L.M., Hectors M.P.C., Defouw N.J., Demacker P.N.M., Stalenhoef A.F.H. Vitamin E and fatty acid intervention does not attenuate the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Arterioscler. Thromb. Vasc. Biol. 15:1995;290-297.
199. Kleinveld H.A., Demacker P.N.M., Stalenhoef A.F.H. Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Arterioscler. Thromb. 14:1994;1386-1391.
200. Fruebis J., Carew T.E., Palinski W. Effect of vitamin E on atherogenesis in LDL receptor-deficient rabbits. Atherosclerosis. 117:1995;217-224.
201. Shaish A., Daugherty A., O'Sullivan F., Schonfeld G., Heinecke J.W. Beta-carotene inhibits atherosclerosis in hypercholesterolemic rabbits. J. Clin. Invest. 96:1995;2075-2082.
202. Tijburg L.B.M., Wiseman S.A., Meijer G.W., Weststrate J.A. Effects of green tea, black tea and dietary lipophilic antioxidants on LDL oxidizability and atherosclerosis in hypercholesterolaemic rabbits. Atherosclerosis. 135:1997;37-47.
203. De Rijke Y.B., Verwey H.F., Vogelezang C.J.M., Van Der Velde E.A., Princen H.M.G., Van Der Laarse A., Bruschke A.V.G., Van Berkel T.J.C. Enhanced susceptibility of low-density lipoproteins to oxidation in coronary bypass patients with progression of atherosclerosis. Clin. Chim. Acta. 243:1995;137-149.
204. Oleary V.J., Tilling L., Fleetwood G., Stone D., Darley-Usmar V. The resistance of low density lipoprotein to oxidation promoted by copper and its use as an index of antioxidant therapy. Atherosclerosis. 119:1996;169-179.
205. Tangirala R.K., Casanada F., Miller E., Witztum J.L., Steinberg D., Palinski W. Effect of the antioxidant N,N′-diphenyl 1,4-phenylenediamine (DPPD) on atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 15:1995;1625-1630.
206. Halevy D., Thiery J., Nagel D., Arnold S., Erdmann E., Hofling B., Cremer P., Seidel D. Increased oxidation of LDL in patients with coronary artery disease is independent from dietary vitamins E and C. Arterioscler. Thromb. Vasc. Biol. 17:1997;1432-1437.
207. Nielsen F., Mikkelsen B.B., Nielsen J.B., Andersen H.R., Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress Reference interval and effects of life-style factors . Clin. Chem. 43:1997;1209-1214.
208. Lagendijk J., Ubbink J.B., Delport R., Hayward Vermaak W.J., Human J.A. Ubiquinol/ubiquinone ratio as a marker of oxidative stress in coronary artery disease. Res. Commun. Mol. Pathol. Pharmacol. 95:1997;11-20.
209. Uusitupa M.I.J., Niskanen L., Luoma J., Vilja P., Mercuri M., Rauramaa R., Ylä-Herttuala S. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 16:1996;1236-1242.
210. Bui M.N., Sack M.N., Moutsatsos G., Lu D.Y., Katz P., McCown R., Breall J.A., Rackley C.E. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. Am. Heart J. 131:1996;663-667.
211. Wójcicki J., Rózewicka L., Barcew-Wiszniewska B., Samochowiec L., Juźwiak S., Kadlubowska D., Tustanowski S., Juzyszyn Z. Effect of selenium and vitamin E on the development of experimental atherosclerosis in rabbits. Atherosclerosis. 87:1991;9-16.
212. Mahfouz M.M., Kawano H., Kummerow F.A. Effect of cholesterol-rich diets with and without added vitamins E and C on the severity of atherosclerosis in rabbits. Am. J. Clin. Nutr. 66:1997;1240-1249.
213. Mao S.J.T., Yates M.T., Parker R.A., Chi E.M., Jackson R.L. Attenuation of atherosclerosis in a modified strain of hypercholesterolemic Watanabe rabbits with use of a probucol analogue (MDL 29,311) that does not lower serum cholesterol. Arterioscler. Thromb. 11:1991;1266-1275.
214. Williams R.J., Motteram J.M., Sharp C.H., Gallagher P.J. Dietary vitamin-E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis. 94:1992;153-159.
215. Verlangieri A.J., Bush M.J. Effects of d-alpha-tocopherol supplementation on experimentally induced primate atherosclerosis. J. Am. Coll. Nutr. 11:1992;131-138.
216. Donaldson W.E. Atherosclerosis in cholesterol-fed Japanese quail Evidence for amelioration by dietary vitamin E . Poult. Sci. 61:1982;2097-2102.
217. Smith T.L., Kummerow F.A. Effect of dietary vitamin E on plasma lipids and atherogenesis in restricted ovulator chickens. Atherosclerosis. 75:1989;105-109.
218. Schwenke D.C., Behr S.R. Vitamin E combined with selenium inhibits atherosclerosis in hypercholesterolemic rabbits independently of effects on plasma cholesterol concentration. Circ Res. 83:1998;366-377.
219. Godfried S.L., Combs G.F., Saroka J.M., Dillingham L.A. Potentiation of atherosclerotic lesions in rabbits by a high dietary level of vitamin E. Br. J. Nutr. 61:1989;607-617.
220. Beetens J.R., Coene M.C., Veheyen A., Zonnekeyn L., Herman A.G. Vitamin C increases the prostacyclin production and decreases the vascular lesions in experimental atherosclerosis in rabbits. Prostaglandins. 32:1986;335-352.
221. Hayashi E., Yamada J., Kunitomo M., Terada M., Sato M. Fundamental studies on physiological and pharmacological actions of L-ascorbate 2-sulfate V. On the hypolipidemic and antiatherosclerotic effects of L-ascorbate 2-sulfate in rabbits . Jpn. J. Pharmacol. 28:1978;61-72.
222. Brattsand R. Actions of vitamins A and E and some nicotinic acid derivatives on plasma lipids and on lipid infiltration of aorta in cholesterol-fed rabbits. Atherosclerosis. 22:1975;47-61.
223. Rapola J.M., Virtamo J., Haukka J.K., Heinonen O.P., Albanes D., Taylor P.R., Huttunen J.K. Effect of vitamin E and beta carotene on the incidence of angina pectoris A randomized, double-blind, controlled trial . JAMA. 275:1996;693-698.
224. Heinonen O.P., Huttunen J.K., Albanes D., Haapakoski J., Palmgren J., Pietinen P., Pikkarainen J., Rautalahti M., Virtamo J., Edwards B.K., Greenwald P., Hartman A.M., Taylor P.R., Haukka J., Jarvinen P., Malila N., Rapola S., Jokinen P., Karjalainen J., Lauronen J., Mutikainen J., Sarjakoski M., Suorsa A., Tiainen M., Verkasalo M., Barrett M., Alfthan G., Ehnholm C., Gref C.G., Sundvall J., Haapa E., Ovaskainen M.L., Palvaalhola M., Roos E., Pukkala E., Teppo L., Frick H., Pasternack A., Brown B.W., Demets D.L., Kokkola K., Tala E., Aalto E., Maenpaa V., Tienhaara L., Jarvinen M., Kuuliala I., Linko L., Mikkola E., et al. Effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 330:1994;1029-1035.
225. Rapola J.M., Virtamo J., Ripatti S., Huttunen J.K., Albanes D., Taylor P.R., Heinonen O.P. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 349:1997;1715-1720.
226. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., Mitchinson M.J., Brown M.J. Randomised controlled trial of vitamin E in patients with coronary disease Cambridge Heart Antioxidant Study (CHAOS) . Lancet. 347:1996;781-786.
227. Marchioli R., Marfisi R.M., Carinci F., Tognoni G. Meta-analysis, clinical trials, and transferability of research results into practice The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease . Arch. Intern. Med. 156:1996;1158-1172.
228. Weber P., Bendich A., Schalch W. Vitamin C and human health - A review of recent data relevant to human requirements. Int. J. Vitam. Nutr. Res. 66:1996;19-30.
229. Tardif J.C., Cote G., Lesperance J., Bourassa M., Lambert J., Doucet S., Bilodeau L., Nattel S., Deguise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N. Engl. J. Med. 337:1997;365-372.
230. Yokoi H., Daida H., Kuwabara Y., Nishikawa H., Takatsu F., Tomihara H., Nakata Y., Kutsumi Y., Ohshima S., Nishiyama S., Seki A., Kato K., Nishimura S., Kanoh T., Yamaguchi H. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty The probucol angioplasty restenosis trial . J. Am. Coll. Cardiol. 30:1997;855-862.
231. Steiner M., Glantz M., Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. Am. J. Clin. Nutr. 62:1995;S1381-S1384.
232. Hennekens C.H., Buring J.E., Manson J.E., Stampfer M., Rosner B., Cook N.R., Belanger C., Lamotte F., Gaziano J.M., Ridker P.M., Willett W., Peto R. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334:1996;1145-1149.
233. Greenberg E.R., Baron J.A., Karagas M.R., Stukel T.A., Nierenberg D.W., Stevens M.M., Mandel J.S., Haile R.W. Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation. JAMA. 275:1996;699-703.
234. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J., Cullen M.R., Glass A., Keogh J.P., Meyskens F.L., Valanis B., Williams J.H., Barnhart S., Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334:1996;1150-1155.
235. Mark S.D., Wang W., Fraumeni J.F., Li J.Y., Taylor P.R., Wang G.Q., Guo W., Dawsey S.M., Li B., Blot W.J. Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation The Linxian nutrition intervention trial . Am. J. Epidemiol. 143:1996;658-664.
236. Bonorden W.R., Pariza M.W. Antioxidant nutrients and protection from free radicals. Kotsonis F.N., Mackey M., Hjelle J. Nutritional Toxicology. 1994;19-48 Raven Press, New York, USA.
237. Manson J.E., Gaziano J.M., Spelsberg A., Ridker P.M., Cooke N.R., Burling J.E., Willet W.C., Hennekens C.H. A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, Design, and Methods. Ann. Epidemiol. 5:1995;261-269.
238. The HOPE (Heart Outcomes Prevention Evaluation) Study The design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events . Can. J. Cardiol. 12:1996;127-137.
239. Lonn E.M., Yusuf S., Doris C.I., Sabine M.J., Dzavik V., Hutchison K., Riley W.A., Tucker J., Pogue J., Taylor W. Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E SECURE . Am. J. Cardiol. 78:1996;914-919.
240. Gerstein H.C., Bosch J., Pogue J., Taylor D.W., Zinman B., Yusuf S. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes The MICRO-HOPE Study . Diabetes Care. 19:1996;1225-1228.
241. Hennekens C.H., Gaziano J.M., Manson J.E., Buring J.E. Antioxidant vitamin-cardiovascular disease hypothesis is still promising, but still unproven The need for randomized trials . Am. J. Clin. Nutr. 62:1995;S1377-S1380.
242. Simon E., Paul J.L., Soni T., Simon A., Moatti N. Plasma and erythrocyte vitamin E content in asymptomatic hypercholesterolemic subjects. Clin. Chem. 43:1997;285-289.
243. Aviram M., Dankner G., Cogan U., Hochgraf E., Brook J.G. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages - In vitro and in vivo studies. Metabolism. 41:1992;229-235.
244. Palomaki A., Malminiemi K., Metsaketela T. Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment. FEBS. Lett. 410:1997;254-258.
245. Salonen R., Nyyssonen K., Porkkalasarataho E., Salonen J.T. The Kuopio Atherosclerosis Prevention Study (KAPS) Effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression . Am. J. Cardiol. 76:1995;C34-C39.
246. Bredie S.J.H., Debruin T.W.A., Demacker P.N.M., Kastelein J.J.P., Stalenhoef A.F.H. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am. J. Cardiol. 75:1995;348-353.
247. Hussein O., Schlezinger S., Rosenblat M., Keidar S., Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis. 128:1997;11-18.
248. Sakai M., Kobori S., Matsumura T., Biwa T., Sato Y., Takemura T., Hakamata H., Horiuchi S., Shichiri M. HMG-coa reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis. 133:1997;51-59.
249. Parik T., Allikmets K., Teesalu R., Zilmer M. Oxidative stress and hyperinsulinaemia in essential hypertension Different facets of increased risk . J. Hypertension. 14:1996;407-410.
250. Solzbach U., Hornig B., Jeserich M., Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation. 96:1997;1513-1519.
251. Giugliano D., Ceriello A., Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 19:1996;257-267.
252. Kang S.S., Wong P.W.K., Malinow M.R. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu. Rev. Nutr. 12:1992;279-298.
253. Dudman N.P.B., Wilcken D.E.L., Stocker R. Circulating lipid hydroperoxide levels in human hyperhomocysteinemia - Relevance to development of arteriosclerosis. Arterioscler. Thromb. 13:1993;512-516.
254. Mukai K., Daifuku K., Yokoyama S., Nakano M. Stopped-flow investigation of antioxidant activity of estrogens in solution. Biochim. Biophys. Acta. 1035:1990;348-352.
255. Feingold I.B., Longhurst P.A., Colby H.D. Regulation of adrenal and hepatic alpha-tocopherol content by androgens and estrogens. Biochim. Biophys. Acta. 1176:1993;192-196.
256. Landvik S.V., Diplock A.T., Packer L. Efficacy of vitamin E in human health and disease. Cadenas E., Packer L. Handbook of Antioxidants. 1996;63-87 Marcel Dekker, New York, USA.
257. Plotnick G.D., Corretti M.C., Vogel R.A. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA. 278:1997;1682-1686.
258. Toborek M., Kopiecznagrzebieniak E., Drozdz M., Wieczorek M. Increased lipid peroxidation as a mechanism of methionine-induced atherosclerosis in rabbits. Atherosclerosis. 115:1995;217-224.
259. Burton G.W., Joyce A., Ingold K.U. Is vitamin E the only lipid soluble, chain-breaking antioxidant in human blood plasma and erythrocyte membranes? Arch. Biochem. Biophys. 221:1983;281-290.
260. Sies H., Stahl W. Vitamins E and C, beta-carotene, and other carotenoids as antioxidants. Am. J. Clin. Nutr. 62:1995;S1315-S1321.
261. Jialal I., Grundy S.M. Preservation of the endogenous antioxidants in low density lipoprotein by ascorbate but not probucol during oxidative modification. J. Clin. Invest. 87:1991;597-601.
262. Kagan V.E., Serbinova E.A., Forte T., Scita G., Packer L. Recycling of vitamin-E in human low density lipoproteins. J. Lipid Res. 33:1992;385-397.
263. Vatassery G.T., Smith W.E., Quach H.T. Ascorbic acid, glutathione and synthetic antioxidants prevent the oxidation of vitamin E in platelets. Lipids. 24:1989;1043-1047.
264. Chan A.C., Tran K., Raynor T., Ganz P.R., Chow C.K. Regeneration of vitamin E in human platelets. J. Biol. Chem. 266:1991;17290-17295.
265. Leedle R.A., Aust S.D. The effect of glutathione on the vitamin E requirement for inhibition of liver microsomal lipid peroxidation. Lipids. 25:1990;241-245.
266. Palamanda J.R., Kehrer J.P. Involvement of vitamin E and protein thiols in the inhibition of microsomal lipid peroxidation by glutathione. Lipids. 28:1993;427-431.
267. Broquist H.P. Buthionine sulfoximine, an experimental tool to induce glutathione deficiency Elucidation of glutathione and ascorbate in their role as antioxidants . Nutr. Rev. 50:1992;110-111.
268. Winkler B.S., Orselli S.M., Rex T.S. The redox couple between glutathione and ascorbic acid A chemical and physiological perspective . Free Radic. Biol. Med. 17:1994;333-349.
269. Antunes F., Salvador A., Pinto R.E. PHGPx and phospholipase A(2)/GPx Comparative importance on the reduction of hydroperoxides in rat liver mitochondria . Free Radic. Biol. Med. 19:1995;669-677.
270. Sattler W., Maiorino M., Stocker R. Reduction of HDL- and LDL-associated cholesterylester and phospholipid hydroperoxides by phospholipid hydroperoxide glutathione peroxidase and ebselen (Pz 51). Arch. Biochem. Biophys. 309:1994;214-221.
271. Thomas J.P., Geiger P.G., Girotti A.W. Lethal damage to endothelial cells by oxidized low density lipoprotein - Role of selenoperoxidases in cytoprotection against lipid hydroperoxide-mediated and iron-mediated reactions. J. Lipid Res. 34:1993;479-490.
272. Rotruck J.T., Pope A.L., Ganther H.E., Swanson A.B., Hafeman D.G., Hoekstra W.G. Selenium Biochemical role as a component of glutathione peroxidase . Science. 179:1973;588-590.
273. Papas A.M. Oil-soluble antioxidants in foods. Toxicol. Ind. Health. 9:1993;123-150.
274. Ohrvall M., Sundlof G., Vessby B. Gamma, but not alpha, tocopherol levels in serum are reduced in coronary heart disease patients. J. Intern. Med. 239:1996;111-117.
275. Cooney R.V., Franke A.A., Harwood P.J., Hatchpigott V., Custer L.J., Mordan L.J. Gamma-tocopherol detoxification of nitrogen dioxide - Superiority to alpha-tocopherol. Proc. Natl. Acad. Sci. U.S.A. 90:1993;1771-1775.
276. Hertog M.G.L., Kromhout D., Aravanis C., Blackburn H., Buzina R., Fidanza F., Giampaoli S., Jansen A., Menotti A., Nedeljkovic S., Pekkarinen M., Simic B.S., Toshima H., Feskens E.J.M., Hollman P.C.H., Katan M.E. Flavonoid intake and long-term risk of coronary heart disease and cancer in the Seven Countries Study. Arch. Intern. Med. 155:1995;381-386.
277. Superko H.R., Krauss R.M. Coronary artery disease regression convincing evidence for the benefit of aggressive lipoprotein management . Circulation. 90:1994;1056-1069.
278. Paterson R.W., Paat J.J., Steele G.H., Hathaway S.C., Wong J.G. Impact of intensive lipid modulation on angiographically defined coronary disease clinical implications . South. Med. J. 87:1994;236-242.
279. Waters D. Plaque stabilization A mechanism for the beneficial effect of lipid-lowering therapies in angiography studies . Prog. Cardiovasc. Dis. 37:1994;107-120.
280. Hebert P.R., Gaziano J.M., Chan K.S., Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality An overview of randomized trials . JAMA. 278:1997;313-321.
281. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. 332:1995;488-493.